Ladenburg analyst Matthew Kaplan lowered the firm’s price target on United Therapeutics to $264 from $268 and keeps a Buy rating on the shares post the Q3 report. The analyst expects the growth of treprostinil-based products to largely be driven by the growing market potential for Tyvaso.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UTHR:
- United Therapeutics reports Q3 EPS $5.38, consensus $5.08
- United Therapeutics: First patient enrolled in Phase 3 TETON PPF study
- United Therapeutics to acquire Miromatrix Medical
- UTHR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- United Therapeutics sues Tyvaso for patent infringement already found invalid